Study The Effect Of Adding Rebamipide On The Eradication Therapy For Helicobacter Pylori Infection

Abstract

H. pylori infection is a leading etiological factor for various gastroduodenal diseases, including chronic gastritis, peptic ulcers and duodenal ulcers, as well as adenocarcinoma and MALT lymphoma of the stomach. In the last decad, there has been a negative trend in the effectiveness of classic eradication therapy regimens of H.pylori, which has largely been determined by the emergence and spread of antibiotic resistance. In this regard the addition of the gastroprotective drug Rebamipide to eradication regimens has shown great potential of increasing efficacy of antibiotics. Rebamipide does not have a direct anti-helicobacter action; however, in experimental studies, it was shown that it inhibits the adhesion of H. pylori to epithelial cells of the gastric mucosa. We aimed to study the effect of adding Rebamipide on the eradication therapy for helicobacter pylori infection in Egyptian patient. This study included 100 patients with H.Pylori infection who had been confirmed by tissue histopathology. All patients proved to be H.pylori positive had been categorized in two groups:- 1- Group I (Control group ) without Rebamipide (50 patients) :- -Clarithromycin 500 mg twice daily + Amoxicillin 1gm twice daily +Tinidazole 500 mg twice daily + Omeprazole 40 mg twice daily. All were for 14 day. (Standard treatment) According to The American Gastroenterological Association (AGA)